🔎 Trials Near Me

Beranda › Kanker Paru Non-Sel Kecil › Kentucky › Lexington

Uji klinis Kanker Paru Non-Sel Kecil di Lexington, KY

23 studi untuk Kanker Paru Non-Sel Kecil mencari peserta di lokasi sekitar Lexington (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.

Teks studi resmi (Bahasa Inggris)

Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

Menerima pesertaFase 3
  • Baptist Health Lexington, Lexington
  • Baptist Health Hamburg, Lexington
  • University of Kentucky/Markey Cancer Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Okt 2026 · NCT04267848

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

Menerima pesertaFase 2
  • University of Kentucky Chandler Medical Center ( Site 0019), Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 1 Okt 2026 · NCT06780085

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Menerima pesertaFase 3
  • University of Kentucky Chandler Medical Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 30 Sep 2026 · NCT07361497

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • Research Site, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

Menerima pesertaFase 3
  • Baptist Health Lexington, Lexington
  • Baptist Health Hamburg, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06890598

Pan-tumor MRD Study

Menerima pesertaStudi observasional
  • Baptist Health Lexington, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 24 Sep 2026 · NCT06605404

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Menerima pesertaFase 3
  • Baptist Health Lexington, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT06561386

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

Menerima pesertaFase 2/3
  • Baptist Health Lexington, Lexington
  • University of Kentucky Chandler Medical Center (UKCMC) - Markey Cancer Center (Lucille P. Markey Cancer Center), Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT06712316

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Menerima pesertaFase 3
  • Research Site, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Menerima pesertaFase 3
  • Clinical Study Site, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Sep 2026 · NCT06767514

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

Menerima pesertaFase 2/3
  • Lexington Medical Cancer Center Hematology/Oncology, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04613596

Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib

Menerima pesertaFase 1/2
  • Markey Cancer Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Sep 2026 · NCT04486833

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Menerima pesertaFase 3
  • CHI Saint Joseph Cancer Center - East, Lexington
  • University of Kentucky Chandler Medical Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 8 Sep 2026 · NCT06119581

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

Menerima pesertaFase 2
  • University of Kentucky ( Site 0019), Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06731907

Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer

Menerima pesertaFase 1
  • University of Kentucky Chandler Medical Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jul 2026 · NCT05142189

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors

Menerima pesertaFase 1
  • UK Markey Cancer Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 11 Jun 2026 · NCT05283330

Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • University of Kentucky/Markey Cancer Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 3 Jun 2026 · NCT05642572

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • University of Kentucky/Markey Cancer Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 6 Mei 2026 · NCT06116682

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2/3
  • University of Kentucky/Markey Cancer Center, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06616584

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Menerima pesertaFase 2
  • University of Kentucky/Markey Cancer Center, Lexington
18 Minutes · Semua jenis kelamin · Diperbarui 5 Mei 2026 · NCT06031688

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

Menerima pesertaStudi observasional
  • Saint Joseph Hospital East, Lexington
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 17 Mar 2026 · NCT06418204

Uji klinis Kanker Paru Non-Sel Kecil di kota lain

Studi lain di Lexington

Dari ClinicalTrials.gov, data diambil 6 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.